ONTAK has also been shown to decrease the number of circulating CD4+CD25+ Treg cells and the suppression mediated by these cells in patients with ovarian, lung, breast, and pancreatic cancer (Curiel, 2007b). This evidence concerns the gene CD4 and familial pancreatic carcinoma.